Adimmune Corp. signs benefit-sharing agreement with WHOStaff Writer, with CNATaiwan-based vaccine maker Adimmune Corp. on Tuesday announced it has signed an agreement with the World Health Organization (WHO) to receive early biological samples of emerging influenza variants. In a press release, Adimmune said it had signed the pact, known as a Standard Material Transfer Agreement 2 (SMTA2) under the WHO’s Pandemic Influenza Preparedness (PIP) Framework. The contract will allow Adimmune to receive biological samples of new influenza viruses with pandemic potential from the WHO, thus giving it a head start on developing vaccines or antiviral drugs, the company said. The name of Adimmune Corp is pictured at the company’s headquarters in Taichung in an undated photograph. In signing the pact, Adimmune became the first Taiwanese pharmaceutical company to enter an influenza- related material transfer agreement with the WHO, and only the 14th worldwide, the company said.
